CAS NO: | 70323-44-3 |
包装: | 50ug |
市场价: | 8500元 |
Physical Appearance | Each vial, when reconstituted to 500 μl with water, contains 50 μg of pertussis toxin in 0.01 M sodium phosphate, 0.05 M sodium chloride, pH 7.0 |
Storage | 2-8°C (as supplied), handle gently; do not vortex; do not freeze |
M.Wt | 1724.44 |
Cas No. | 70323-44-3 |
Formula | C87H162N14O16S2 |
Solubility | Soluble in H2O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
百日咳杆菌合成AB5型外毒素Pertussis toxin(PT)。PT主要由蛋白质组成,可以引起百日咳。
体外:PT对先天性免疫应答显效。PT对人单核细胞源树突状细胞(MDDC)的效应,包括成熟,由cAMP所调节[1]。
体内:在NIH小鼠或BALB/c小鼠离体气管中,PT不影响其舒张与收缩功能,但显著地减少氯化钾或缓解去甲肾上腺素诱导的最大气管收缩。在雄性Wistar大鼠离体肠系膜阻力性小动脉血管中,PT降低其对去甲肾上腺素的敏感性[2]。
临床试验:PT是一种无细胞百日咳疫苗,用于增强年轻人和老年人免疫力,以减少社区传染并增强保护。受感染的老年人常无症状。无细胞百日咳疫苗改善百日咳症状,同时也作用于轻度以及无症状感染。此外,在婴儿群体中,无细胞百日咳疫苗可以显著降低传染率[3]。
参考文献:
[1] Bagley KC, Abdelwahab SF, Tuskan RG, Fouts TR, Lewis GK. Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway. J Leukoc Biol. 2002 Nov;72(5):962-9.
[2] van Meijeren CE, Vleeming W, van de Kuil T, Manni J, Kegler D, Hendriksen CF, de Wildt DJ. In vivo pertussis toxin treatment reduces contraction of rat resistance arteries but not that of mouse trachea. Eur J Pharmacol. 2004 Mar 19;488(1-3):127-35.
[3] Ward JI, Cherry JD, Chang SJ, Partridge S, Keitel W, Edwards K, Lee M, Treanor J, Greenberg DP, Barenkamp S, Bernstein DI, Edelman R; APERT Study Group. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis. 2006 Jul 15;43(2):151-7. Epub 2006 Jun 5.